Shares of Revance Therapeutics, Inc. (RVNC) have gained 74.1% over the past four weeks to close the last trading session at $6.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.20 indicates a potential upside of 55%. The average comprises eight short-term price targets ranging from a low of $6.60 to a high of $25, with a standard deviation of $6.30. While the lowest estima ...